share_log

Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target

Stifel Upgrades Denali Therapeutics to Buy, Announces $37 Price Target

Stifel將Denali Therapeutics評級上調至買入,目標價爲37美元。
Benzinga ·  12/16 19:58  · 評級/大行評級

Stifel analyst Paul Mattels upgrades Denali Therapeutics (NASDAQ:DNLI) from Hold to Buy and announces $37 price target.

Stifel分析師保羅·美泰爾將德納利療法(納斯達克股票代碼:DNLI)從持有上調至買入,並宣佈目標股價爲37美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論